The recent`personal view' 1 supports the establishment of commercial links between NHS laboratories and the pharmaceutical industry. In their discussion the authors af®rm the need to work to the highest laboratory standards. Their premise that,`in order to perform work for the pharmaceutical industry . . . laboratories need to conform to the standards of GLP', although widely held, is wrong. Currently, the legal need for Good Laboratory Practice (GLP) in analysis of clinical samples is clearly absent. The UK GLP regulations expressly exclude clinical studies from their remit, reserving themselves for non-clinical studies [in the context of the pharmaceutical industry, non-clinical means pre-clinical (animal) work]. The Medicines Control Agency (MCA) which administers the GLP compliance programme does not admit to the scheme laboratories which exclusively conduct clinical analyses. As a consequence, such laboratories could never claim formal GLP compliance on any work conducted.
The commercial need for a quality standard is, however, clearly present. There is an undoubted requirement for any work contracted out by the pharmaceutical companies to be performed to the highest standards possible. In the industry's search for subcontractors, potential suitors are judged on their ability to produce accredited credentials. GLP, above all other standards, strikes a chord internationally with the clinical divisions of pharmaceutical companies whose sister, pre-clinical, divisions will be all too familiar with its existence. So, GLP usually becomes the standard that is demanded and promised.
Unfortunately, the present situation allows a duality of GLP standards to exist. GLP is a worthy standard to emulate but those who do so to produce a GLP-like environment can often overestimate the extent of their compliance and fall some way short of the full GLP require-ments. To adopt the standards of the GLP regulations is not to produce a GLP-compliant product.
As our laboratory is a member of the UK GLP compliance programme, we are keen to preserve the value and promote the understanding of GLP. With little sign of a shift in policy to allow clinical laboratories to enter into the GLP compliance programme, more and more clinical laboratories will be left to provide a self-concocted amalgam of standards for which there is a demand but no formal body to regulate. This, in our experience, will undoubtedly lead to further confusion, further diminution of the GLP imprimatur and lack of product clarity for customers. 
GRAHAM SHAW ATHOLL JOHNSTON DAVID W HOLT

Authors' reply
The purpose of our article was to demonstrate the bene®ts that working with the pharmaceutical industry can bring to NHS laboratories and to describe some of the issues which need to be surmounted before undertaking such work. In so doing, we hoped that other NHS laboratories would be encouraged to consider the option of working with the pharmaceutical industry. The above correspondence is correct in pointing out that there is no legal need for laboratories undertaking clinical work to conform to the standards of Good Laboratory Practice (GLP)
Letters
Ann Clin Biochem 2001; 38: 411±416 and, indeed, that unless laboratories undertake pre-clinical (e.g. animal) work, they cannot be inspected and admitted to the GLP compliance programme. This remains a frustration to laboratories such as ours since we are unable to, and do not, claim formal`GLP compliance'. In practice, however, adherence to the principles of GLP is ensured through regular audits by the commercial sponsor, so the`need' to conform to GLP standards is borne by commercial pressures rather than statutory legislation. More recently, we have worked to the principles of Good Clinical Practice (GCP) by combining the principles of both GLP and relevant sections of the International Committee for Harmonization Guideline of GCP. Again, there is currently no legal requirement that laboratories undertaking such work should conform to this standard. However, we have liaised with the Medicines Control Agency who have undertaken a`voluntary' GCP inspection of our laboratory. It is our understanding that the European Commission is preparing legislation to ensure the implementation of GCP in the conduct of clinical trials, including laboratories supporting such studies (see http://europa.eu.int, Commission Proposal 599PC0193, for further information).
EDMUND LAMB ROB ROSE
Department of Clinical Biochemistry Kent and Canterbury Hospital Ethelbert Road Canterbury CT1 3NG, UK
Gender differences in urinary excretion rates of cortisol and androgen metabolites
Using gas chromatography, Shamim et al. 1 have demonstrated increased urinary total cortisol metabolite excretion in men compared to women, supporting our earlier radioimmunoassay study in which we observed higher urinary free cortisol (UFC) excretion in men. 2 As in our study, they did not observe a relationship between cortisol excretion and body mass index. However, reanalysis of our data did demonstrate a relationship with body surface area. 3 It would be interesting to know whether the same is true of the present study, although there remains no explanation for this relationship. 4 The sensitivity and speci®city of 24 h UFC measurement as a diagnostic test for Cushing's syndrome have been widely accepted as being approximately 95%. 5 This was reaf®rmed in a recent study 6 which, despite again observing signi®cantly increased cortisol excretion in males compared to females, used a single combined upper limit of normal to evaluate the performance of the test. The differences between UFC and total cortisol metabolite excretion in males and females are considerable, yet few laboratories routinely report results accompanied by sex-related reference ranges. The diagnostic performance of this test might well improve if appropriate reference ranges were used.
Evaluation of effect of analytical imprecision in maternal serum screening for Down's syndrome
Like Benn and Collins, 1 we have been concerned for some time about the effect of analytical imprecision in maternal serum screening for Down's syndrome. As early as 1991 I reported on the analytical error in the calculation of risk in Down's syndrome screening 2 and showed the wide con®dence intervals surrounding the calculated risk, particularly when more than two analytes were used. I also showed that deterioration in analytical performance could lead to con®dence intervals that would result in sig-ni®cant misclassi®cation errors, i.e. changes in risk interpretation between increased risk and not at increased risk. In 1991 3 we also proposed that consideration be given to reporting risks along with their con®dence interval, and showed with our a-fetoprotein/b human chorionic gonadotrophin two-marker protocol 4 how this con®dence interval varied exponentially with decreasing risk. At the time we established that at a risk of 1 in 300 (our cut-off at that time), our two-analyte protocol gave a coef®cient of variation (CV) of 10´1%. Further consideration towards implementing the con®dence interval approach led us to conclude, as did Benn and Collins, 1 that the inclusion of an estimate of imprecision in individual laboratory reports would appear confusing to patients, who often have dif®culty understanding risk concepts. However, within the laboratory over the past decade we have found the concept of risk variability and its monitoring to be a useful quality tool. In 1993 I outlined 5 our experience with the use of risk as a quality control (QC) parameter in Down's syndrome screening programmes and showed that in order to keep risks at the 1 in 250 cut-off with a CV of 10%, the analytical performance for each marker had to be maintained close to 3´5% CV or less.
In essence, our procedure has been to run three levels of control material speci®cally targeted at ranges appropriate for normal pregnancies, Down's syndrome pregnancies and neural tube defect-affected pregnancies. These control materials are run daily before any patient's samples are processed. From the results of the appropriate controls we take the concentrations and, using a ®xed gestational age and ®xed maternal age (chosen to give risks close to the clinical decision point), we then calculate the multiple of the median and the Down's syndrome risk. We aim to keep the same control material in use for at least 2 years, and to keep the risk within a +2 standard deviation limit (using a running 200-day period). If the risk QC fails, then further scrutiny of individual analyte QC is carried out, with analyser recalibration considered as a possible measure.
We have found such a system very useful in both our second-trimester 6 and ®rst-trimester 7 screening programmes. Our analytical system for the past 3 years has been the Brahms Kryptor time-resolved¯uorescence system, and Tables 1 and 2 summarize the performance we have achieved over the past year.
I concur wholeheartedly with Benn and Collins 1 that individual laboratories do need to evaluate their own performance critically, taking all possible measures to ensure that they are providing high-quality risk estimates. I believe the QC of the risk approach is a simple effective additional tool that laboratories could implement in order to give themselves, their clinicians Authors' reply Kevin Spencer has suggested a novel approach to the quality control of maternal serum screening that involves calculating a Down syndrome risk for control samples. For those analytical runs in which the control risks fall outside acceptable limits, the individual analyte values are reviewed to determine the source of the problem. A disadvantage to this approach is that drift of two assays may be in opposite directions, resulting in approximately constant risks but potentially suboptimal assays. This problem would presumably arise more frequently for those laboratories providing three-or fourmarker testing. In addition, the extent of this undetected drift could be larger for those providing screening based on higher numbers of markers, because several markers may change simultaneously. At least for programmes providing three-or four-marker screening, an indepen-dent review of each component test would appear to be the more practical approach.
Our laboratory now provides the quad screen [maternal serum a-fetoprotein (MS-AFP), human chorionic gonadotrophin (hCG), unconjugated estriol (uE3) and inhibin-A (INH-A)]. Three controls at clinically signi®cant levels are run for MS-AFP, hCG and uE3, and two levels for INH-A. For automated analyser tests (MS-AFP and hCG) the controls are analysed before patients' specimens, and one control is repeated at the end of the run to check for assay drift. For our radioimmunoassay (uE3) and enzyme immunoassay (INH-A), the controls are randomly integrated in the runs. Acceptance of runs is based on comparison of concentrations against the expected range of past values (mean +2 SD). In addition to these measures, patients' sample medians are reviewed on a monthly basis.
A patient-speci®c risk is provided for all patients. Similar to Dr Spencer's experience, 1 we have recently reported that the actual level of risk reported for screen-positive patients is an important factor in determining amniocentesis utilization. 2 We therefore continue to emphasize the importance of both precise clinical information and analytical precision to provide the most reliable risk assessments. 
PETER BENN ROXANNE COLLINS
Solid-phase extraction as an alternative to dichloromethane in analysis of urine free cortisol
It is dif®cult to understand why Dr Wassell and colleagues 1 did not do what they set out to do, i.e. compare solid-phase extraction with dichloromethane extraction in the analysis of urinary free cortisol. Instead, they compared the results of a solid-phase extraction and cortisol assay on the Bayer ACS:180 with those of dichloromethane extraction and cortisol assay on the DPC Immulite, thereby introducing into the comparison the calibration, precision and speci®city of the second immunoassay as additional and apparently unrecognized variables. It appears that in this work the Immulite method has been accorded the status of a reference method, an honour which no immunoassay could claim for this analyte and one which DPC will undoubtedly have the wisdom to decline.
As the authors indicate in their ®rst paragraph, speci®city is the main reason for doing extractions, and yet speci®city has been paid scant attention. Urine from a patient with Cushing's disease was used for the assessment of recovery rather than normal urine spiked with known amounts of cortisol. Equally inexplicably, a comparison of the assay of extracts made by the solid-phase method with the assay of unextracted urines was used, in calculations of dubious validity, to derive an estimate of the comparability of the two extraction methods, a relationship which could have been demonstrated directly with far less work and much greater reliability.
It is possible that the authors' conclusion is correct, that solid-phase extraction is a viable alternative to dichloromethane extraction in the assay of urinary free cortisol, but no such conclusion could be drawn from this work. 
JOAN BUTLER
Authors' reply
The main aim of our study was to establish a method on our new immunoassay analyser (ACS180) for the measurement of urinary free cortisol to replace the existing Immulite assay. Of overriding importance was the need to replace dichloromethane extraction with something simpler, because we have always found it to be a labour-and time-intensive procedure.
We chose solid-phase extraction because it has been demonstrated to be ef®cient for the extraction of cortisol from urine in HPLC methods, even though it is not widely used for extracting samples for immunoassay. We agree with Joan Butler that the Immulite assay does not deserve reference status; it was merely used as a comparator because, like most routine laboratories, we do not have access to a mass spectrometer. It has always been our policy to compare a new method with the existing assay when changing methods. We demonstrated improved precision on the new method, which encouraged us to change over. Since then, our UKNEQAS returns have been as good as previous results.
We realize that the recovery experiment was not classic, but would point out that the measurement of pathological urines is more usual in a clinical setting. 
JULIE WASSELL
Lactulose±mannitol intestinal permeability test: a useful screening test for adult coeliac disease
Our experience of using a dual sugar intestinal permeability test (in this laboratory, lactulose/ rhamnose validated against cellobiose/mannitol) is primarily in a gastrointestinal outpatient population. We have found the test to give greater sensitivity (94%) and lower speci®city (75%) for coeliac disease in this population than that found in the`clinical' population selected by positive serology by Johnston et al. 1 We suggest that the test is unsuitable for ®rstline screening for the following reasons:
(a) Although the test is not dif®cult for patients to undertake as outpatients, it is more onerous than a single blood test. (b) Non-steroidal drug or alcohol intake is not excluded in population screening, and such intake can lead to temporarily abnormal results. (c) The low speci®city of the test would require additional testing (usually serological) before proceeding to a biopsy in an asymptomatic individual.
We therefore suggest that a sugar permeability test is inappropriate as a ®rst-line screening test in the general adult population. We have found the test to be of greatest value in excluding coeliac disease in patients presenting initially to the gastrointestinal outpatient clinic (owing to its high negative predictive value), and therefore it is useful as a second-line test to try to minimize the number of endoscopic procedures. It is also of use in following the progress of patients with biopsy-con®rmed pathology. 
K KINGSTONE H R GILLETT
Authors' reply
We accept that other groups have reported a higher sensitivity for the use of the intestinal permeability tests in detecting coeliac disease. Our lower value for sensitivity (81 versus 94%) may relate to smaller groups of patients/controls (21 healthy controls, 16 untreated symptomatic coeliacs and seven treated coeliacs) than those referred to by Kingstone and Gillett.
We have not suggested that the intestinal permeability test should be used as a ®rst-line screening test for coeliac disease, even though we have found its sensitivity and negative predictive value to be higher than those of the individual serological tests. As stated by Kingstone and Gillett, a blood sample is much more practical as a ®rst-line screening test, and it should be noted that our sample population was ®rst preselected on the basis of serological positivity. We agree that false positives with the intestinal permeability test can occur with patients taking nonsteroidal anti-in¯ammatory drugs (which excluded 25% of subjects in our study) and alcohol. It is true that the low speci®city of the permeability test in our study would require serological con®rmation before proceeding to biopsy.
At the time of the study our routine clinical practice was to test for both IgA-antigliadin and IgA-antiendomysial antibodies and to decide on duodenal biopsy on the basis of clinical suspicion, combined with the serological results. Using the combination of these two antibodies would have raised the sensitivity of these tests to 100% for detecting coeliac disease in the screened population, but reduced the speci®city considerably (28%).
Therefore, we agree that serological testing is more practical and suitable than the sugar permeability test for screening the adult population, and it is emphasized that our sample population was preselected on the grounds of positive serology. Although the permeability test may have a role to play as a second-line test, we would maintain that it should not limit the number of endoscopic procedures, as duodenal biopsy remains the gold standard for diagnosing coeliac disease.
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